FDA Approves Lantheus Holdings' Imaging Agent For Prostate Cancer

Lantheus Holdings Inc.'s (LNTH) PYLARIFY injection, a prostate specific membrane antigen-targeted positron emission tomography imaging agent, has been approved by the FDA.

from RTT - Top Story https://ift.tt/34rr3M8
via IFTTT